A Nanoparticle-Based Immunoassay on Facemasks for Evaluating Neutrophilic Airway Inflammation in COPD Patients
Patients with chronic obstructive pulmonary disease (COPD) often experience acute exacerbations characterized by elevated neutrophilic inflammation in the lungs. Currently, this condition is diagnosed through visual inspection of sputum color and volume, a method prone to personal bias and unsuitabl...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Biosensors |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6374/15/5/323 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849327714452897792 |
|---|---|
| author | Bartomeu Mestre Nuria Toledo-Pons Andreu Vaquer Sofia Tejada Antonio Clemente Amanda Iglesias Meritxell López Ruth Engonga Sabina Perelló Borja G. Cosío Roberto de la Rica |
| author_facet | Bartomeu Mestre Nuria Toledo-Pons Andreu Vaquer Sofia Tejada Antonio Clemente Amanda Iglesias Meritxell López Ruth Engonga Sabina Perelló Borja G. Cosío Roberto de la Rica |
| author_sort | Bartomeu Mestre |
| collection | DOAJ |
| description | Patients with chronic obstructive pulmonary disease (COPD) often experience acute exacerbations characterized by elevated neutrophilic inflammation in the lungs. Currently, this condition is diagnosed through visual inspection of sputum color and volume, a method prone to personal bias and unsuitable for patients who are unable to expectorate spontaneously. In this manuscript, we present a novel approach for measuring and monitoring exhaled myeloperoxidase (MPO), a biomarker of neutrophilic airway inflammation, without the need for sputum analysis. The method involves analyzing an unmodified surgical facemask worn by the patient for 30 min using biosensing decals that transfer antibody-coated nanoparticles. These colloids specifically interact with MPO trapped by the facemask in a dose-dependent manner, enabling the quantification of MPO levels, with a dynamic range up to 3 · 10<sup>1</sup> µg·mL<sup>−1</sup>. The proposed diagnostic approach successfully differentiated patients with acute exacerbations from stable patients with 100% sensitivity and specificity. Healthy individuals also showed significantly lower MPO levels compared to COPD patients. Our results suggest that facemask analysis could be a non-invasive diagnostic tool for airway diseases, particularly in patients unable to expectorate. |
| format | Article |
| id | doaj-art-492d855079ee4c9f8e07334c8b474ef4 |
| institution | Kabale University |
| issn | 2079-6374 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biosensors |
| spelling | doaj-art-492d855079ee4c9f8e07334c8b474ef42025-08-20T03:47:48ZengMDPI AGBiosensors2079-63742025-05-0115532310.3390/bios15050323A Nanoparticle-Based Immunoassay on Facemasks for Evaluating Neutrophilic Airway Inflammation in COPD PatientsBartomeu Mestre0Nuria Toledo-Pons1Andreu Vaquer2Sofia Tejada3Antonio Clemente4Amanda Iglesias5Meritxell López6Ruth Engonga7Sabina Perelló8Borja G. Cosío9Roberto de la Rica10Multidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, SpainInflamación, Reparación y Cáncer en Enfermedades Respiratorias (I-RESPIRE) Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, SpainMultidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, SpainMultidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, SpainGroup of Innovation in Immunopathology of Infections (GTERi), Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, SpainInflamación, Reparación y Cáncer en Enfermedades Respiratorias (I-RESPIRE) Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, SpainInflamación, Reparación y Cáncer en Enfermedades Respiratorias (I-RESPIRE) Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, SpainInflamación, Reparación y Cáncer en Enfermedades Respiratorias (I-RESPIRE) Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, SpainInflamación, Reparación y Cáncer en Enfermedades Respiratorias (I-RESPIRE) Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, SpainInflamación, Reparación y Cáncer en Enfermedades Respiratorias (I-RESPIRE) Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, SpainMultidisciplinary Sepsis Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, SpainPatients with chronic obstructive pulmonary disease (COPD) often experience acute exacerbations characterized by elevated neutrophilic inflammation in the lungs. Currently, this condition is diagnosed through visual inspection of sputum color and volume, a method prone to personal bias and unsuitable for patients who are unable to expectorate spontaneously. In this manuscript, we present a novel approach for measuring and monitoring exhaled myeloperoxidase (MPO), a biomarker of neutrophilic airway inflammation, without the need for sputum analysis. The method involves analyzing an unmodified surgical facemask worn by the patient for 30 min using biosensing decals that transfer antibody-coated nanoparticles. These colloids specifically interact with MPO trapped by the facemask in a dose-dependent manner, enabling the quantification of MPO levels, with a dynamic range up to 3 · 10<sup>1</sup> µg·mL<sup>−1</sup>. The proposed diagnostic approach successfully differentiated patients with acute exacerbations from stable patients with 100% sensitivity and specificity. Healthy individuals also showed significantly lower MPO levels compared to COPD patients. Our results suggest that facemask analysis could be a non-invasive diagnostic tool for airway diseases, particularly in patients unable to expectorate.https://www.mdpi.com/2079-6374/15/5/323chronic obstructive pulmonary diseasebreathmyeloperoxidaseexacerbationbiosensor |
| spellingShingle | Bartomeu Mestre Nuria Toledo-Pons Andreu Vaquer Sofia Tejada Antonio Clemente Amanda Iglesias Meritxell López Ruth Engonga Sabina Perelló Borja G. Cosío Roberto de la Rica A Nanoparticle-Based Immunoassay on Facemasks for Evaluating Neutrophilic Airway Inflammation in COPD Patients Biosensors chronic obstructive pulmonary disease breath myeloperoxidase exacerbation biosensor |
| title | A Nanoparticle-Based Immunoassay on Facemasks for Evaluating Neutrophilic Airway Inflammation in COPD Patients |
| title_full | A Nanoparticle-Based Immunoassay on Facemasks for Evaluating Neutrophilic Airway Inflammation in COPD Patients |
| title_fullStr | A Nanoparticle-Based Immunoassay on Facemasks for Evaluating Neutrophilic Airway Inflammation in COPD Patients |
| title_full_unstemmed | A Nanoparticle-Based Immunoassay on Facemasks for Evaluating Neutrophilic Airway Inflammation in COPD Patients |
| title_short | A Nanoparticle-Based Immunoassay on Facemasks for Evaluating Neutrophilic Airway Inflammation in COPD Patients |
| title_sort | nanoparticle based immunoassay on facemasks for evaluating neutrophilic airway inflammation in copd patients |
| topic | chronic obstructive pulmonary disease breath myeloperoxidase exacerbation biosensor |
| url | https://www.mdpi.com/2079-6374/15/5/323 |
| work_keys_str_mv | AT bartomeumestre ananoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT nuriatoledopons ananoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT andreuvaquer ananoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT sofiatejada ananoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT antonioclemente ananoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT amandaiglesias ananoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT meritxelllopez ananoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT ruthengonga ananoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT sabinaperello ananoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT borjagcosio ananoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT robertodelarica ananoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT bartomeumestre nanoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT nuriatoledopons nanoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT andreuvaquer nanoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT sofiatejada nanoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT antonioclemente nanoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT amandaiglesias nanoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT meritxelllopez nanoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT ruthengonga nanoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT sabinaperello nanoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT borjagcosio nanoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients AT robertodelarica nanoparticlebasedimmunoassayonfacemasksforevaluatingneutrophilicairwayinflammationincopdpatients |